The randomized, double-blind, phase III KEYNOTE-412 study investigated the efficacy and safety of pembrolizumab plus chemoradiation vs placebo plus chemoradiation in patients with locally advanced head and neck squamous cell carcinoma. Findings were presented by Machiels et al at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA5).
